Immuno-oncology

Topic immuno-oncology Infectious diseases

Scrip

Gilead Says 16 Cancer Centers Getting Ready To Administer Yescarta

Within weeks of its acquisition of Kite, Gilead is working to launch its first immuno-oncology drug, with a goal of training.

Topic immuno-oncology

Datamonitor Healthcare

Immuno-Oncology Overview

This is an overview of the field of immuno-oncology and the various immuno-oncology classes. Immuno-oncology is one of the most promising and fastest growing areas of cancer research, as well

Topic immuno-oncology

Datamonitor Healthcare

PD-1/PD-L1 Inhibitors: The First Wave of Immuno-Oncology

Recently, Informa Pharma Intelligence conduced an insightful webinar regarding the current market landscape and outlook for immuno-oncology.

Topic immuno-oncology

Scrip

BMS' Opdivo Approval In CRC Overshadowed By Keytruda Dominance

The US FDA has approved BMS' Opdivo for previously treated patients with some forms of colorectal cancer, however direct competition from Merck's Keytruda may limit its success.

Topic immuno-oncology Cancer

Scrip

PD-1 Data Emerges In Cervical Cancer

Leading immunotherapy agents are beginning to report early-stage data from monotherapy and combination trials in advanced cervical cancer – a treatment area with very few approved options.

Topic Cancer immuno-oncology Research Strategy

Scrip

Immuno-Oncology Outlook: Getting To The Root Of Head And Neck Cancer

As PD-1 inhibitors march toward earlier-stage head and neck cancers, researchers consider ways to improve the precision of immunotherapy through better patient selection and combinations for this accessible tumor type.

Topic Cancer immuno-oncology

Scrip

Boehringer Ingelheim's Partnering Focus: An Interview With Ioannis Sapountzis

Trying to catch up with peers in both immuno-oncology and NASH, the German pharma has assigned Sapountzis to lead its US business development efforts.

Topic Cancer immuno-oncology

Pink Sheet

Immuno-oncology Drugs And The Trouble With Market Access

The clinical potential of immuno-oncology drugs does not seem to be reflected in approaches by health technology assessment bodies, with different interpretations of data.

Topic immuno-oncology